Back to Newsroom

Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus

ZUG, Switzerland, Oct. 11, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced additional clinical data as well as updates to its development plan for KeyzilenTM (AM-101) in acute inner ear tinnitus.

Click here to read the full release